PCMC
NTLA icon

Planning Capital Management Corporation’s Intellia Therapeutics NTLA Stock Holding History

Planning Capital Management Corporation’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$62 Hold
3
– – ﹤0.01% 733
2024
Q2 		$68 Buy
+3
New +$71 ﹤0.01% 675

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Planning Capital Management Corporation's NTLA Position: Q3 2024 in Review

Planning Capital Management Corporation held its Intellia Therapeutics (NTLA) position steady in Q3 2024 at 3 shares worth $62. The position accounts for ﹤0.01% of the portfolio, ranked #733.

Planning Capital Management Corporation first reported a position in NTLA in Q2 2024 and has held it in 2 quarters since. The position peaked at $68 in Q2 2024. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Planning Capital Management Corporation held 3 shares of Intellia Therapeutics worth $62 as of Q3 2024.
  • Planning Capital Management Corporation left its Intellia Therapeutics share count unchanged in Q3 2024.
  • Intellia Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #733 holding.
  • Planning Capital Management Corporation first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Planning Capital Management Corporation's Intellia Therapeutics position peaked at $68 in Q2 2024.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.